Current guidelines recommend germline and/or somatic testing for homologous recombination gene mutations, including BRCA1 and BRCA2, in all patients with metastatic PCA to identify candidates for PARPi therapy [22]. The gene discussed is BRCA2; the disease is posterior cortical atrophy.